MediWound Ltd.

MDWD

IL0011316309

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-06 EDT			5-day change	1st Jan Change
16.92 ^USD	-0.47%		+5.49%	+66.37%

05-29	Transcript : MediWound Ltd., Q1 2024 Earnings Call, May 29, 2024
05-29	Earnings Flash (MDWD) MEDIWOUND Reports Q1 Revenue $5M, vs. Street Est of $4.7M	MT

MediWound Ltd. Appoints Boaz Gur-Lavie as Chief Financial Officer

June 11, 2019 at 07:36 am

MediWound Ltd. announced the appointment of Mr. Boaz Gur-Lavie as Chief Financial Officer, effective June 11, 2019. Prior to joining MediWound, Mr. Gur-Lavie co-founded Center for Digital innovation.

Latest news about MediWound Ltd.

Transcript : MediWound Ltd., Q1 2024 Earnings Call, May 29, 2024	05-29
Earnings Flash (MDWD) MEDIWOUND Reports Q1 Revenue $5M, vs. Street Est of $4.7M	05-29	MT
MediWound Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-29	CI
MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026	03-21	CI
Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024	03-21
MediWound Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Earnings Flash (MDWD) MEDIWOUND Posts Q4 Revenue $5.3M, vs. Street Est of $5.3M	03-21	MT
MediWound Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	02-12	MT
MediWound Shares Rise After Positive Results From EscharEx Comparison Study	02-12	MT
Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study	02-12	CI
MediWound's NexoBrid Application to Include Pediatric Patients Accepted for Review by FDA	01-09	MT
Mediwound Announces That FDA Has Accepted for Review the Supplement to the Nexobrid BLA to Include Pediatric Patients with Severe Thermal Burns	01-09	CI
MediWound Secures $6.7 Million in DoD Funding for Field Burn Treatment Therapy	12-28	MT
Mediwound Ltd. Secures Additional U.S. Department of Defense Funding to Advance Nexobrid® Development for the U.S. Army	12-28	CI
Mediwound Ltd. Announces Publication of Escharex Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads	12-21	CI
Transcript : MediWound Ltd., Q3 2023 Earnings Call, Nov 21, 2023	11-21
Earnings Flash (MDWD) MEDIWOUND Reports Q3 Revenue $4.8M, vs. Street Est of $4.8M	11-21	MT
MediWound Ltd. Appoints Shmulik Hess as Chief Operating Officer and Chief Commercial Officer, Effective December 1, 2023	11-21	CI
MediWound Wins European Agency Approval for NexoBrid Expansion to All Age Groups in Deep Thermal Burn Cases	11-13	MT
MediWound Ltd Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients	11-13	CI
MediWound, PolyMedics Innovations Sign Agreement to Promote NexoBrid in Europe	11-08	MT
MediWound Ltd. Announces Collaboration with PolyMedics Innovations for NexoBrid Distribution in Europe	11-08	CI
MediWound Collaborates With 3M Unit on Drug Candidate EscharEx Late-Stage Study	23-10-11	MT
MediWound Deploys Emergency Supply of NexoBrid to Help Burn Victims in Israel	23-10-09	MT

Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

Sector

Pharmaceuticals

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for MediWound Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.92 USD

Average target price

28.5 USD

Spread / Average Target

+68.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
MEDIWOUND LTD.	+66.37%	158M
CSL LIMITED	+0.61%	91.72B
SAMSUNG BIOLOGICS CO.,LTD.	0.00%	39.44B
BIOGEN INC.	-10.35%	34.47B
UCB	+64.64%	26.7B
BIOMARIN PHARMACEUTICAL INC.	-16.15%	15.13B
INCYTE CORPORATION	-6.98%	13.27B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.77%	11.74B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-49.19%	10.54B
SWEDISH ORPHAN BIOVITRUM AB	+8.09%	9.41B

Biopharmaceuticals

MediWound Ltd.

Equities

MDWD

IL0011316309

Pharmaceuticals

MediWound Ltd. Appoints Boaz Gur-Lavie as Chief Financial Officer

Latest news about MediWound Ltd.

Chart MediWound Ltd.

Company Profile

Income Statement Evolution

Ratings for MediWound Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals